ERBB2 and neoplasm: The aim of our study was to assess if the immunopanel consisted of triple negative phenotype (ER, PgR, HER2) with the addition of basal cytokeratins (CK5/6, 14, 17) or vimentin could better delineate a basal type tumour group and better predict patient survival when compared to only pure ER, PgR, HER2 negative phenotype.